Equillium Buys Metacrine For Its Cash, Will Outsource Lead Drug Candidate

All-Stock Deal Merges Two San Diego Firms

 
• By Mandy Jackson

Deal Snapshot: Equillium will gain $33m, extending its cash runway into 2024 and past several upcoming milestones, but it will seek a strategic partner for Metacrine’s stalled FXR agonist MET642.

Isometric arrow formed by two merging black and white lines on turquoise blue
Equillium will use Metacrine's cash for its own programs • Source: Shutterstock

More from Deals

More from Business